Vanguard Capital Management
ESLA icon

Vanguard Capital Management’s Estrella Immunopharma ESLA Stock Holding History

Vanguard Capital Management’s Portfolio ESLA Stock Details ESLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$434K Buy
416,852
+34,383
+9% +$45K ﹤0.01% 3733
2026
Q1 		$405K Buy
+382,469
New +$440K ﹤0.01% 3708

Other funds holding ESLA

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $91.6B AUM 29.2% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Capital Management's ESLA Position: Q2 2026 in Review

Vanguard Capital Management increased its Estrella Immunopharma (ESLA) stake by 9% in Q2 2026, buying an estimated $45K and bringing the position to 416,852 shares worth $434K. The position accounts for ﹤0.01% of the portfolio, ranked #3733.

Vanguard Capital Management first reported a position in ESLA in Q1 2026 and has held it in 2 quarters since. 15 funds tracked by Wall St. Rank hold ESLA as of Q2 2026.

  • Vanguard Capital Management held 416,852 shares of Estrella Immunopharma worth $434K as of Q2 2026.
  • Vanguard Capital Management bought 34,383 Estrella Immunopharma shares in Q2 2026, an estimated $45K.
  • Estrella Immunopharma made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3733 holding.
  • Vanguard Capital Management first reported a position in Estrella Immunopharma in Q1 2026 and has held it in 2 quarters since.
  • 15 funds tracked by Wall St. Rank held Estrella Immunopharma as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.